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Abstract
Background: Health-related quality-of-life (HRQOL) assessment with EORTC QLQ-C30 was prognostic for overall
survival (OS) in patients with advance-stage hepatocellular carcinoma (HCC), but no data existed for early-stage
patients. The HCC-specific QLQ-HCC18 has not been evaluated for prognostic value in HCC patients. Utilization of
raw HRQOL data in clinical setting has been impractical and non-meaningful. Therefore we developed index scores
of QLQ-C30 and QLQ-HCC18 in an attempt to enable clinical utilization of these HRQOL measurements. This study
investigates the prognostic significance of QLQ-C30, QLQ-HCC18 and C30/HCC18 index-scores in patients with
newly diagnosed HCC which encompasses all stages.
Methods: From 2007–2011, 517 patients were prospectively recruited. HRQOL was assessed at diagnosis using
QLQ-C30 and QLQ-HCC18; C30 and HCC18 index-scores were calculated from raw HRQOL data. Cox regression
was performed using continuous, dichotomized QLQ-C30 and QLQ-HCC18 variables, or index-scores, together
with clinical factors to identify independent factors for OS. Various multivariate models were validated with
c-index and bootstrapping for 1000 replications.
Results: Four hundred and seventy two patients had complete HRQOL data. Their median OS was 8.6 months. In
multivariate analysis, independent prognostic HRQOL variables for OS were QLQ-C30 pain (HR 1.346 [1.092–1.661],
p = 0.0055), QLQ-C30 physical functioning (HR 0.652 [0.495–0.860], p = 0.0024); QLQ-HCC18 pain (HR 1.382 [1.089–1.
754], p = 0.0077) and QLQ-HCC18 fatigue (HR 1.441 [1.132–1.833], p = 0.0030). C30 index-score (HR 2.143 [1.616–2.
841], p < 0.0001) and HCC18 index-score (HR 1.957 [1.411–2.715], p < 0.0001) were highly significant factors for OS.
The median OS of patients with C30 index-score of 0–20, 21–40, 41–60, 61–100 were 16.4, 7.3, 3.1, 1.8 months
respectively (p < 0.0001); while for HCC18 index-score: 16.4, 6.0, 2.8, 1.8 months respectively (p < 0.0001). All the
multivariate models were validated, with mean optimism <0.01. The bootstrap validated c-index was 0.78.
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Conclusions: QLQ-C30 and QLQ-HCC18 were prognostic for OS in patients with newly diagnosed HCC irrespective
of stage. Both C30 and HCC18 index-scores were highly significant prognostic factors for OS in newly diagnosed
HCC patients. Index-scoring provides an effective way to summarize, analyze and interpret raw HRQOL data, and
renders QLQ-C30 and QLQ-HCC18 meaningful and communicable in clinical practice. Index-scores could potentially
serve as a standardized tool for future HRQOL research.
Keywords: Health-related quality-of-life, QLQ-HCC18, QLQ-C30, Index-score, Prognosis, Overall survival, Hepatocellular
carcinoma, Liver cancer
Background
Three studies have shown health-related quality-of-life
(HRQOL) being prognostic for overall survival (OS) in
patients with advance-stage hepatocellular carcinoma
(HCC) [1–3]. These used general cancer HRQOL meas-
urement tools, namely the European Organization for
Research and Treatment of Cancer (EORTC) QLQ-C30
[4] and Spitzer QOL index [5]. On the other hand, one
negative study recruited both early- and advance-stage
HCC patients and used another general cancer HRQOL
measurement, Functional Assessment of Cancer Therapy
– General (FACT-G) [6, 7]. To date, there has been no
study evaluating the prognostic value of QLQ-C30 for pa-
tients with newly diagnosed HCC which encompasses all
stages.
Patients with HCC often suffer from chronic liver dis-
ease. In Asia, this is mainly due to chronic hepatitis B
virus (HBV) infection [8–10]. Therefore liver-specific
HRQOL measurement could be more relevant for these
patients. EORTC QLQ-HCC18 [11] is a specific HRQOL
module which addresses QOL issues specific for patients
with primary liver cancer. It has been validated in Asian
HCC patients [12, 13] and many scales of QLQ-HCC18
have been reported to enable the identification of pa-
tients with different clinical conditions. However, the
prognostic value of EORTC QLQ-HCC18 in HCC pa-
tients has not been evaluated.
So far it has been a common practice to analyze raw
HRQOL data as a collection of continuous variables, and
various HRQOL factors have been proven to be prognos-
tic for survival in various malignancies. Despite the wide
utilization of EORTC QLQ-C30, there has been no do-
main/item identified to be consistently prognostic [14].
Difficulties in HRQOL research were well recognized:
multi-collinearity among numerous raw HRQOL data
causing multivariate analysis model instability, overfitting
of variables leading to excessive multiple comparisons and
type I error [14, 15], and lack of means to meaningfully
translate raw HRQOL data into clinical use. Diouf et al.
dichotomized all HRQOL data at a universal cut-off at 50
for analysis. This addressed the issues of multi-collinearity
and overfitting and provided a way to interpret HRQOL
data by clinicians [3]. A separate analysis was performed
to determine the true cut-off for various domains/items,
and these cut-offs have been considered to be potentially
population-specific [16].
In an attempt to determine a generalizable way to
analyze and interpret HRQOL data while minimizing
multi-collinearity and over-fitting, we derived two
index-scores, namely the C30 and HCC18 index-scores,
to represent all domains and items within the EORTC
QLQ-C30 and QLQ-HCC18 respectively.
The objectives of this study are: (1) to evaluate the
prognostic value of QLQ-C30 in a prospective cohort of
newly diagnosed patient with HCC which encompasses
all stages; (2) to investigate the prognostic significance of
the liver-specific QLQ-HCC18 in this cohort; and (3) to
evaluate the prognostic significance of C30 and HCC18
index-scores.
Methods
From January 2007 to December 2011, all patients with
newly diagnosed HCC presented to the multidisciplinary
hepatoma clinic of Prince of Wales Hospital were con-
sidered for recruitment. The study was approved by the
Joint Chinese University of Hong Kong-New Territories
East Cluster Clinical Research Ethics Committee.
Eligibility criteria included: adult patients with newly
diagnosed and treatment-naïve HCC; the diagnosis of
HCC as confirmed by either histology, the combination
of radiological and biochemical findings (space-occupying
lesion in the liver with raised α-fetoprotein (AFP ≥ 400ug/
L), or 2 typical radiological findings with ultrasonography,
triphasic computed tomography, angiography or magnetic
resonance imaging; ability to read and comprehend
Chinese was a pre-requisite. Patients were excluded if they
had history of malignancy, encephalopathy or cognitive
impairment.
Treatment
After confirmation of diagnosis and stage, patients were
offered appropriate treatment as clinically indicated.
Treatment options included surgical resection, local abla-
tive therapies – radiofrequency ablation (RFA) or percu-
taneous ethanol injection (PEI), transarterial therapies -
transarterial chemo-embolisation (TACE) or transarterial
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injection of lipiodol-ethanol mixture (LEM), systemic
therapies – sorafenib, chemotherapy, clinical trials and
best supportive care (BSC) alone.
HRQOL assessment
Consented patients would complete two HRQOL ques-
tionnaires: the EORTC QLQ-C30 and QLQ-HCC18, at
their baseline visit before treatment commencement.
EORTC QLQ-C30
The Chinese version of QLQ-C30 was used [4]. It is a
cancer-specific 30-item questionnaire composed of mul-
tiple items that reflect the multidimensionality of
HRQOL construct, presented in multiple-point Likert
scales. These items are grouped into 9 domains and 6
single items. It incorporates 5 functional domains (phys-
ical, role, cognitive, emotional and social), 3 symptom
domains (fatigue, pain, nausea and vomiting) and a glo-
bal health and QOL domain. The remaining 6 single
items assess additional 5 symptoms commonly reported
by cancer patients (dyspnea, appetite loss, sleep disturb-
ance, constipation and diarrhea) as well as perceived fi-
nancial problem. All domains and scales were converted
to scores ranging from 0 to 100 according to the scoring
manual [17]. A higher score for a functional or global
QOL scale represents a relatively higher/healthier level
of functioning or global QOL, whereas a higher score
for a symptom/problem scale represents a more severe
symptom/problem.
EORTC QLQ-HCC18
The Chinese version of EORTC QLQ-HCC18 [11] in-
cludes 18 multi-item scales. These items are grouped into
6 domains namely fatigue, body image, jaundice, nutrition,
pain and fever. Two remaining single items address ab-
dominal swelling and sex life. All scales were grouped and
converted to score 0 to 100 according to the scoring man-
ual; a higher score represents a more severe symptom or
problem.
C30 and HCC18 index-scores
C30 and HCC18 index-scores were derived in order to
have an overall representation of all domains/items in
QLQ-C30 and QLQ-HCC18 respectively.
To calculate C30 index-score, individual functioning
scale was subtracted by 100 to convert them into hav-
ing the same meaning as symptom/problem scales.
These 6 subtracted scores were subsequently summed
with the 9 symptom/problem scales, and then divided
by 15 (the total number of QLQ-C30 scales). A higher
C30 index-score reflects a worse overall HRQOL. This
is the mathematical formula:
C30 index‐score ¼ Σ 100‐Physical functioningð Þ;

100‐Role functioningÞ; 100‐Emotional functioningð Þ;
100‐Cognitive functioningð Þ; 100‐Social functioningð Þ;
100‐global QOLð Þ; scores of Fatigue; Nausea=vomiting;
Pain; Dyspnoea; Insomnia; Appetite loss; Constipation;
Diarrhea; Financial Diffculty  15
HCC18 index-score was defined as the sum of all 8
QLQ-HCC18 symptom/problem scales divided by 8 (the
total number of QLQ-HCC18 scales). A higher HCC18
index-score reflects a worse overall HRQOL. This is the
mathematical formula:
HCC18 indexscore ¼ Σðscores of Fatigue;Body Image;
Jaundice; Nutrition; Pain; Fever; Sex life; Abdominal
distensionÞ  8
Clinical factors and follow-up
Demographic, clinical and laboratory parameters were
collected. All patients were followed up for treatment
and monitoring until death or last contact.
Statistical analysis
Standard descriptive analyses were performed to assess
sample characteristics. OS was defined as the time from
the date-of-consent to date-of-death. In the absence of
death confirmation, survival time was censored at the
date-of-last-seen. Survival estimation was performed by
the Kaplan-Meier method, and compared using the log-
rank test.
Only patients with complete HRQOL data were in-
cluded in statistical analysis. EORTC QLQ-C30 and
QLQ-HCC18 scales were included in the prognostic
factor analysis as (i) continuous variables, (ii) dichoto-
mized (≥50 or <50) variables, and (iii) index-scores. Uni-
variate analysis was performed with baseline HRQOL
scores and non-overlapping clinical variables to identify
factors that influenced survival using Cox proportional-
hazards regression model. A stepwise model building
procedure was used for multivariate analysis, based on a
significance value of 0.05 for both inclusion and exclusion
of prognostic factors. For analyses involving continuous
variables, higher scores (better function and worse symp-
toms/problems respectively) were compared to lower
scores (worse function or better symptoms/problems);
whereas for dichotomized data, symptom/problem do-
main/item scores of ≥50 (worse scores) were compared to
<50 (better scores), while functional domain scores of <50
(worse scores) were compared to ≥50 (better scores).
Treatment options were grouped into curative-intent
treatment (surgical/locoablative therapies), palliative-intent
treatment (transarterial/systemic therapies) or BSC.
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Performance of the final multivariate models were
assessed and compared by Harrell’s concordance-index
(c-index) [18]. The c-index estimates the probability of
concordance between predicted and observed responses.
A value of 1.0 indicates perfect separation of patients
with different outcomes, and a value of 0.5 indicates no
predictive discrimination. Internal validation was carried
out by comparing the c-index of each model with the c-
indexes of 1000 bootstrap replications to obtain opti-
misms, which were averaged and bootstrap-corrected
performance was estimated.
The statistical analyses were performed using SAS ver-
sion 9.3 software package. A p-value of less than 0.05
was considered significant. The c-index and 95% confi-
dence intervals (CI) of the different models were calcu-
lated by using the SAS macro program.
Results
Patient characteristics
Among the 517 patients who consented, 472 (91%) had
complete HRQOL data and were included for analysis.
Table 1 listed the clinical characteristics of these patients.
The median age at diagnosis was 60, the majority were
male (89%). Most patients had Eastern Cooperative
Oncology Group (ECOG) performance status 0–1 (94%).
HBV infection was present in 82%, while hepatitis C in
6%. Fifty nine percent had cirrhosis and 68% was of Child-
Pugh class A. Eighteen percent of patients received first-
line curative intent treatment, the rest received palliative
treatment (44%) or BSC (38%).
The median follow-up duration was 29.8 months (95%
CI [26.8–32.8]), 377 patients had died. The median OS
was 8.6 months (95% CI [7.3–10.2]).
Mean scores of QLQ-HCC18 and QLQ-C30 scales
and mean HCC18 and C30 index-scores were listed in
Table 2.
Univariate analysis of HRQOL and clinical factors
Tables 1 and 2 summarized the univariate Cox regres-
sion analyses for clinical variables, QLQ-C30 and QLQ-
HCC18 scores, as well as C30 and HCC18 index-scores.
Univariate HRQOL analysis based on continuous variables
For QLQ-C30, higher (better) scores in all functioning
(e.g. physical functioning, HR 0.432 [0.351–0.533]) or glo-
bal domains were significantly associated with longer OS
(p < 0.03); whereas higher (worse) scores in fatigue, nau-
sea/vomiting, pain (HR 1.865 [1.584–2.197]), dyspnea, in-
somnia, appetite loss, diarrhea and financial difficulties
were significantly associated with shorter OS (p < 0.01).
For QLQ-HCC18, higher (worse) scores in all 8 symp-
tom/problem domains (e.g. fatigue HR 2.381 [1.942–2.919])
were significantly associated with shorter OS (p < 0.05).
Univariate QOL analysis based on dichotomization of
scores
For QLQ-C30, scores ≥50 (better) in global QOL, phys-
ical, role, cognitive and social functioning and scores <50
(better) in all symptom/problem domains (e.g. financial
difficulties HR 1.579 [1.276–1.954]) were significantly
associated with longer OS (p < 0.05).
For QLQ-HCC18, scores ≥50 (worse) in fatigue (HR
2.484 [1.968–3.136]), body image, nutrition, pain, sex life,
abdominal swelling domains were significantly associated
with shorter OS (p < 0.01).
Univariate QOL analysis based on the newly derived index-
scores
Higher C30 index-score (reflecting worse overall func-
tions/symptoms/problems) was significantly associated
with shorter OS (HR 3.658 [2.726–4.909] p < 0.0001).
Higher HCC18 index-score (reflecting worse overall
symptoms/problems) was significantly associated with
shorter OS (HR 3.028 [2.340–3.919] p < 0.0001).
Multivariate analysis of HRQOL data with clinical factors
Table 3 shows the results of the multivariate Cox regres-
sion analyses involving HRQOL variables or index-scores
identified in univariate regression with non-overlapping
clinical factors.
Multivariate Analysis of clinical factors
Multifocal or diffuse HCC, presence of extra-hepatic
metastasis, portal vein thrombosis, hypoalbuminemia,
hyperbilirubinemia, high AFP, alkaline phosphatase and
creatinine were consistently significant clinical factors
associated with shorter OS in all multivariate analyses.
Multivariate HRQOL analysis based on continuous variables
For QLQ-C30, higher (better) score in physical function-
ing (HR 0.652 [0.495–0.860], p = 0.0024) was significantly
associated with longer OS and higher (worse) score in
pain (HR 1.346 [1.092–1.661], p = 0.0055) was significantly
associated with shorter OS.
For QLQ-HCC18, higher (worse) scores in fatigue (HR
1.441 [1.132–1.833], p = 0.0030) and pain (HR 1.382
[1.089–1.754], p = 0.0077) were significantly associated
with shorter OS.
Multivariate QOL analysis based on dichotomization of scores
For QLQ-C30, scores ≥50 (worse) in pain (HR 1.523
[1.192–1.947], p = 0.0008), and financial difficulties (HR
1.331 [1.059–1.673], p = 0.0141) and score <50 (worse) in
physical functioning (HR 1.475 [1.095–1.986], p = 0.0106)
were significant independent factors for shorter OS.
For QLQ-HCC18, worse fatigue score (≥50) (HR 1.805
[1.411–2.310], p < 0.0001) was significantly associated
with shorter OS.
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Figure 1 shows the survival of patients with different
scores in significant dichotomized HRQOL domains/
items. The median OS for patients with better (≥50) and
worse (<50) scores in QLQ-C30 physical functioning
were 10.1 (95%CI 8.6–12.8) and 2.3 months (95% CI
1.9–4.9) respectively (p < 0.0001). The median OS for
patients with better (<50) and worse (≥50) scores in
QLQ-C30 pain were 13.4 (95% CI 9.6–16.4) and 3.3
Table 1 Baseline characteristics and univariate Cox regression analyses of overall survival for patients with complete HRQOL data (n = 472)
n % HR 95% C.I. p-value
Demographics/clinical
Age < = 65 328 69 0.909 0.730–1.131 0.3898
Male gender 419 89 1.299 0.919–1.835 0.1381
ECOG≥ 2 29 6 2.885 1.927–4.317 <0.0001
Laboratory
Hemoglobin <10g/dL 27 6 1.294 0.840–1.995 0.2424
White cell count >10×109/L 64 14 2.507 1.885–3.333 <0.0001
Platelet count < 100×109/L 33 7 1.696 1.158–2.485 0.0067
International normalized ratio >1.4 36 8 1.410 0.945–2.104 0.0922
Creatinine≥ ULN 67 14 1.115 0.833–1.491 0.4644
Bilirubin≥ 20umol/l 239 51 1.974 1.594–2.445 <0.0001
Albumin ≤35g/l 182 39 2.186 1.765–2.708 <0.0001
Alanine aminotransferase >2xULN 81 17 1.567 1.201–2.044 0.0009
Alkaline phosphatase >2xULN 145 31 2.417 1.938–3.014 <0.0001
Underlying liver condition
Hepatitis B surface antigen + 386 82 1.196 0.908–1.575 0.2029
Hepatitis C antibody + 30 6 0.641 0.403–1.019 0.0600
Ascites 278 59 0.894 0.721–1.107 0.3036
Cirrhosis (radiological) 122 26 2.237 1.775–2.820 <0.0001
Child-Pugh class
A 319 68 1.000 - -
B 130 28 2.187 1.740–2.750 <0.0001
C 23 4 4.360 2.774–6.854 <0.0001
Tumor characteristics
α-fetoprotein ≥200 mg/ml 250 53 2.318 1.865–2.882 <0.0001
Tumor morphology
Uninodular 122 26 1.000 - -
Multinodular 143 30 2.097 1.509–2.914 <0.0001
Diffuse 207 44 4.360 3.027–3.822 <0.0001
Extrahepatic metastasis (nodal or distant) 108 23 3.003 2.360–3.822 <0.0001
Portal vein thrombosis 152 32 3.647 2.899–4.587 <0.0001
1st line Treatment
Curative 83 18 1.000 -
Palliative or best supportive care alone 389 82 5.802 3.820–8.810 <0.0001
Surgical treatment 54 12 1.000 -
Local ablative therapies 29 6 2.526 1.131–5.643 0.0238
Trans-arterial therapies 116 25 4.597 2.446–8.637 <0.0001
Systemic therapies 91 19 10.209 5.380–19.372 <0.0001
Best supportive care alone 182 38 15.624 8.442–28.914 <0.0001
ECOG Eastern Cooperative Oncology Group performance status, ULN upper limit of normal, CI confidence interval, HR hazard ratio
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months (95%CI 2.7–4.7) respectively (p < 0.0001), that
of QLQ-C30 financial difficulties were 12.8 (95% CI
9.8–15.9) and 5.2 months (95% CI 4.0–7.8) (p < 0.0001)
and QLQ-HCC18 fatigue were 12.1 (95% CI 9.8–14.8) and
2.6 months (95% CI 1.9–3.1) (p < 0.0001) respectively.
Multivariate QOL analysis based on the newly derived
index-scores
In the multivariate analysis using C30 index-score with
clinical factors, higher (worse) C30 index-score was a
significant independent risk factor for shorter OS (HR
2.143 [1.616–2.841], p < 0.0001).
In the multivariate analysis using HCC18 index-score
with clinical factors, higher (worse) HCC18 index-score
was a significant independent risk factor for shorter OS
(HR 1.957 [1.411–2.715], p < 0.0001).
Figure 2 shows the OS plots for patients with stratified
C30 and HCC18 index-scores respectively. Lower
(better) C30 index-score ranges were associated with
longer OS in a step-wise fashion (p < 0.0001); similarly,
the lower (better) HCC18 index-score ranges, the longer
the OS (p < 0.0001).
The median OS in patients with C30 index-score of
0–20 was 16.4 (95% CI 13.4–22.3) months, that for score
21–40 was 7.3 (95% CI 4.5–10.4) months, score 41–60
Table 2 Baseline HRQOL and univariate analyses using continuous, dichotomized variables, C30 and HCC18 index scores for patients
with complete HRQOL data (n = 472)a
Mean ±SD Continuous variables Dichotomized variablesa
HR [95% CI] p-value HR [95% CI] p-value
EORTC QLQ-C30
Physical Functioning 72.27 23.74 0.432 [0.351–0.533] <0.0001 2.026 [1.571–2.612] <0.0001
Role Functioning 74.61 32.60 0.517 [0.443–0.603] <0.0001 2.108 [1.645–2.702] <0.0001
Emotional Functioning 70.67 25.48 0.777 [0.632–0.954] 0.0164 1.448 [1.100–1.908] 0.0084
Social Functioning 76.80 24.68 0.698 [0.571–0.853] 0.0004 1.611 [1.162–2.234] 0.0042
Cognitive Function 68.46 30.33 0.634 [0.531–0.756] <0.0001 1.573 [1.233–2.007] 0.0003
Global Quality of Life 52.22 26.34 0.515 [0.417–0.635] <0.0001 1.611 [1.299–1.998] <0.0001
Fatigue 42.93 30.23 1.973 [1.657–2.349] <0.0001 2.072 [1.672–2.568] <0.0001
Nausea/Vomiting 11.26 21.41 2.050 [1.643–2.559] <0.0001 2.308 [1.679–3.173] <0.0001
Pain 32.87 31.97 1.865 [1.584–2.197] <0.0001 2.108 [1.698–2.617] <0.0001
Dyspnoea 29.73 31.46 1.396 [1.189–1.639] <0.0001 1.666 [1.314–2.113] <0.0001
Insomnia 41.88 36.41 1.344 [1.162–1.556] <0.0001 1.415 [1.144–1.750] 0.0014
Appetite loss 32.34 35.88 1.923 [1.668–2.217] <0.0001 2.360 [1.889–2.949] <0.0001
Constipation 16.67 27.13 1.201 [0.999–1.444] 0.0512 1.368 [1.021–1.834] 0.0359
Diarrhea 16.45 26.87 1.520 [1.252–1.845] <0.0001 1.666 [1.248–2.224] 0.0005
Financial difficulties 51.20 37.22 1.353 [1.169–1.566] <0.0001 1.579 [1.276–1.954] <0.0001
C30 index score 30.69 19.61 3.658 [2.726–4.909] <0.0001 - -
EORTC QLQ-HCC18
Fatigue 35.23 25.86 2.381 [1.942–2.919] <0.0001 2.484 [1.968–3.136] <0.0001
Body Image 25.35 22.98 2.261 [1.819–2.811] <0.0001 2.167 [1.718–2.733] <0.0001
Jaundice 23.41 22.15 1.289 [1.024–1.623] 0.0307 1.271 [0.977–1.652] 0.0739
Nutrition 26.96 21.35 2.934 [2.317–3.716] <0.0001 2.663 [2.026–3.502] <0.0001
Pain 23.34 24.57 2.107 [1.717–2.587] <0.0001 1.871 [1.465–2.391] <0.0001
Fever 6.60 14.39 1.568 [1.123–2.187] 0.0081 1.697 [0.929–3.099] 0.0851
Sex life 28.74 34.76 1.213 [1.040–1.415] 0.0139 1.436 [1.128–1.828] 0.0033
Abdominal swelling 33.33 35.43 1.721 [1.486–1.994] <0.0001 2.192 [1.752–2.743] <0.0001
HCC18 index score 25.37 17.21 3.028 [2.340–3.919] <0.0001 - -
C30 index-score = ∑ [(100-Physical functioning), (100-Role functioning), (100-Emotional functioning), (100-Cognitive functioning), (100-Social functioning), (100-global
QOL), scores of Fatigue, Nausea/vomiting, Pain, Dyspnoea, Insomnia, Appetite loss, Constipation, Diarrhea, Financial Diffculty] ÷ 15
HCC18 index-score = ∑ (scores of Fatigue, Body Image, Jaundice, Nutrition, Pain, Fever, Sex life, Abdominal distension) ÷ 8
aIn dichotomization, worse (≥50 in symptoms/problem or <50 in functioning/global QOL) scores in QLQ-C30 were analyzed with respect to better scores; worse
(≥50) scores in QLQ-HCC18 were analyzed with respect to better scores
SD standard deviation, CI confidence interval, HR hazard ratio, HRQOL health-related quality of life
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was 3.1 (95%CI 2.3–5.1) months, score 61–80 was 1.8
(95% CI 0.8–4.3) months, and score 81–100 was 1.8
(95% CI 0.5–6) months (p < 0.0001). The median OS of
patients with HCC18 index-score of 0–20 was 16.4 (95%
CI 31-not reached) months, that for score 21–40 was 5.9
(95%CI 4.4–8.9) months, score 41–60 was 2.9 (95% CI
1.6–4.3) months, score 61–80 was 1.8 (95% CI 0.5–3.0)
months, and score 81–100 was 1.8 (95% CI 0.7–2.9)
months (p < 0.0001) (Table 4).
Internal validation of the multivariate cox proportional
hazard models
C-index of original dataset and mean c-index of 1000
bootstrap samples for multivariate model are described
below. Using QLQ-C30 as continuous variables, the cor-
responding values were 0.7872 (95% CI 0.7648–0.8905)
and 0.7891 (95% CI 0.7678–0.8111) respectively. Using
QLQ-C30 as dichotomized variables, the values were
0.7842 (95% CI 0.7617–0.8066) and 0.7878 (95% CI
0.7660–0.8103) respectively. When assessed using C30
index score, the values were 0.7817 (95%CI 0.7591–
0.8043) and 0.7840 (95% CI 0.7626–0.8066) respect-
ively. Using QLQ-HCC18 as continuous variables, the
values were 0.7810 (95% CI 0.7588–0.8032) and 0.7841
(95% CI 0.7638–0.8056) respectively. For QLQ-HCC18
as dichotomized variables, the values were 0.7821
(95%CI 0.7598–0.8043) and 0.7839 (95% CI 0.7621–
0.8072) respectively. For HCC18 index score, the values
were 0.7791 (95% CI 0.7564–0.8018) and 0.7715 (95% CI
0.7604–0.8034) respectively. All optimisms were within
±0.01 (Table 5). The internally validated optimism-
corrected c-index was estimated to be 0.78.
Table 3 Multivariate analysis of HRQOL variables or index scores with significant clinical factors (n = 472)
Continuous QOL variables Dichotomized QOL variables Index score
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
EORTC QLQ-C30
Physical Functioning 0.652 0.495–0.860 0.0024 1.475 1.095–1.986 0.0106 - - -
Pain 1.346 1.092–1.661 0.0055 1.523 1.192–1.947 0.0008 - - -
Financial difficulties - - - 1.331 1.059–1.673 0.0141 - - -
C30 Index score - - - - - - 2.143 1.616–2.841 <0.0001
Portal vein thrombosis 1.723 1.342–2.212 <0.0001 1.702 1.325–2.187 <0.0001 1.661 1.291–2.136 <0.0001
Tumor Morphology – Multinodular 1.604 1.147–2.243 0.0058 1.614 1.152–2.260 0.0054 1.719 1.229–2.403 0.0015
Tumor Morphology – Diffuse 2.449 1.763–3.401 <0.0001 2.556 1.841–3.550 <0.0001 2.636 1.902–3.651 <0.0001
Albumin ≤35g/l 1.442 1.125–1.848 0.0039 1.541 1.199–1.981 0.0007 1.641 1.311–2.055 <0.0001
Bilirubin ≥20umol/l 1.785 1.400–2.275 <0.0001 1.784 1.398–2.277 <0.0001 1.752 1.390–2.208 <0.0001
α-fetoprotein ≥200 ng/ml 1.830 1.439–2.328 <0.0001 1.878 1.476–2.389 <0.0001 1.749 1.380–2.218 <0.0001
Extrahepatic metastasis 1.696 1.303–2.209 <0.0001 1.753 1.342–2.288 <0.0001 1.805 1.386–2.351 <0.0001
Alkaline phosphatase >2xULN 1.456 1.145–1.852 0.0022 1.420 1.116–1.806 0.0043 1.472 1.159–1.870 0.0015
Creatinine≥ ULN 1.538 1.129–2.094 0.0063 1.637 1.204–2.227 0.0017 1.712 1.263–2.322 0.0005
Ascites 1.327 1.015–1.736 0.0385 1.325 1.012–1.734 0.0408 - - -
EORTC QLQ-HCC18
Fatigue 1.441 1.132–1.833 0.0030 1.805 1.411–2.310 <0.0001 - - -
Pain 1.382 1.089–1.754 0.0077 - - - - - -
HCC18 index score - - - - - - 1.957 1.411–2.715 <0.0001
Portal vein thrombosis 1.701 1.320–2.191 <0.0001 1.672 1.295–2.160 <0.0001 1.688 1.312–2.172 <0.0001
Tumor Morphology – Multinodular 1.638 1.172–2.289 0.0038 1.709 1.223–2.388 0.0017 1.681 1.203–2.348 0.0024
Tumor Morphology – Diffuse 2.510 1.805–3.490 <0.0001 2.813 2.034–3.891 <0.0001 2.624 1.893–3.637 <0.0001
Albumin ≤35g/l 1.684 1.344–2.111 <0.0001 1.704 1.360–2.135 <0.0001 1.666 1.329–2.088 <0.0001
Bilirubin ≥20umol/l 1.687 1.333–2.134 <0.0001 1.662 1.316–2.100 <0.0001 1.659 1.312–2.098 <0.0001
α-fetoprotein ≥200 ng/ml 1.744 1.371–2.218 <0.0001 1.805 1.423–2.289 <0.0001 1.735 1.367–2.201 <0.0001
Extrahepatic metastasis 1.788 1.370–2.334 <0.0001 1.830 1.402–2.389 <0.0001 1.773 1.361–2.309 <0.0001
Alkaline phosphatase >2xULN 1.426 1.124–1.810 0.0035 1.341 1.054–1.705 0.0169 1.445 1.139–1.832 0.0024
Creatinine≥ ULN 1.695 1.249–2.301 0.0007 1.600 1.181–2.167 0.0024 1.701 1.253–2.348 0.0007
ULN upper limit of normal, CI confidence interval, HR hazard ratio, HRQOL health-related quality of life
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Multiple comparisons showed no statistically signifi-
cant difference in c-index among related multivariate
cox proportional hazard models (Table 6).
Discussion
This is the first prospective study to demonstrate that the
prognostic significance of QLQ-C30 was not limited to
advance-stage HCC patients but valid for newly diagnosed
patients with various stages of disease. Worse scores in
physical functioning, pain and financial difficulties were
associated with shorter OS in dichotomized variable ana-
lyses, while worse scores in physical functioning and pain
were significant in continuous variable analyses.
This is also the first prospective study to demonstrate
that baseline QLQ-HCC18 is a significant prognostica-
tion tool for OS in newly diagnosed HCC patients.
Worse dichotomized score in fatigue was an independ-
ent prognostic factor for shorter OS, while worse con-
tinuous scores in fatigue and pain were also significant
poor prognostic factors.
Physical functioning domain in the present study
concurred with previous findings by Yeo et al. [1] (where
physical and role functioning, appetite loss were signifi-
cant prognostic factors for OS), and Diouf et al. [3] (where
physical [dichotomized] or role functioning [continuous]
were significant factors).
Fig. 2 Overall survival curves according to stratified C30 and HCC18 index-scores. a Overall survival curves according to stratified C30 index-score.
b Overall survival curves according to stratified HCC18 index-score
Fig. 1 Overall survival curves for significant dichotomized HRQOL factors found in multivariate analysis. a QLQ-C30 Physical Functioning <50 vs
≥50. b QLQ-C30 Pain <50 vs ≥50. c QLQ-C30 Financial difficulties <50 vs ≥50. d QLQ-HCC18 Fatigue <50 vs ≥50. Phys: QLQ-C30 Physical
functioning; HCC fatigue: QLQ-HCC18 Fatigue; OS: overall survival
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The HRQOL factors identified in this study varied
from previous studies and could be due to a number of
reasons. Firstly, patient populations were different, our
study involved early as well as advanced stage HCC pa-
tients while prior studies involved only advanced stage
disease. Secondly, patients of different cultural back-
grounds could have different HRQOL perceptions.
Thirdly, studies conducted more recently carried more
available treatment options than earlier era, which may
have led to differences in perception of disease and thus
HRQOL. Fourthly, although different studies might
utilize the same HRQOL tool, the methodologies of
data analysis varied across trials.
The failure to identify consistent HRQOL factors for
OS across studies makes clinically meaningful utilization
of HRQOL for prognostication difficult. On the other
hand, using simple algorithm and calculation, C30 and
HCC18 index-scores could be derived from the raw data
of all domains and items within QLQ-C30 and QLQ-
HCC18 respectively. It is a meaningful representation of
the overall HRQOL of an individual patient.
The C30 and HCC18 index-scores were proven to be
highly significant prognostic factors for survival, and
were more significant than any individual HRQOL
factor, whether continuous or dichotomized. When the
index-scores were stratified into subgroups, distinct OS
outcomes could be identified. Clinical use of either C30
or HCC18 index-score at baseline provides another
means of survival estimation in patients with newly di-
agnosed HCC apart from conventional staging systems.
Index-score could be calculated in the clinical setting
in a user-friendly manner. With the aid of modern com-
puter technology, patients may be able to self-administer
the QLQ-C30 or QLQ-HCC18 questionnaire and have
the respective index-score generated by handheld devices.
One limitation of this study was the lack of a separate
patient population, for instance, that of a different
geographical or cultural background, to allow external
Table 4 Overall survival data for patients stratified according to C30 and HCC18 index score range (n = 472)
N Median OS (M) 95% CI Survival% at 6M Survival% at 12M Survival% at 24M Survival% at 36M
C30 Index Score
0–20 179 16.4 13.4–22.3 79.7 60.4 41.3 25.6
21–40 153 7.3 4.5–10.4 52.0 39.2 26.0 21.4
41–60 98 3.1 2.3–5.1 36.5 27.0 18.3 8.1
61–80 34 1.8 0.8–4.3 27.5 10.7 7.1 7.1
81–100 8 1.8 0.5–6.0 25.0 - - -
HCC18 Index Score
0–20 213 16.4 31.0-NR 74.6 59.9 43.1 27.8
21–40 169 6.0 4.4–8.9 49.6 33.1 19.3 14.5
41–60 72 2.8 1.6–4.3 31.1 16.7 11.8 5.3
61–80 16 1.8 0.5–3.0 25.0 18.8 9.4 -
81–100 2 1.8 0.7–2.9 - - - -
M month (s), CI, confidence interval, NR not reached
Table 5 Performance and internal validation of all the multivariate cox proportional hazard models
MV model c-index 95% CI Mean c-index from
1000 bootstraps
95% CI based on 1000
bootstrap samples
Optimism Optimism in %
M1 0.7872 0.7648–0.8095 0.7891 0.7678–0.8111 0.0019 0.24%
M2 0.7842 0.7617–0.8066 0.7878 0.7660–0.8103 0.0036 0.46%
M3 0.7817 0.7591–0.8043 0.7840 0.7626–0.8066 0.0023 0.29%
M4 0.7810 0.7588–0.8032 0.7841 0.7638–0.8056 0.0031 0.40%
M5 0.7821 0.7598–0.8043 0.7839 0.7621–0.8072 0.0018 0.23%
M6 0.7791 0.7564–0.8018 0.7715 0.7604–0.8034 −0.0076 −0.96%
MV multivariate, CI confidence interval
M1: the multivariate cox model using QLQ-C30 as continuous variables
M2: the multivariate cox model using QLQ-C30 as dichotomized variables
M3: the multivariate cox model using C30 index score
M4: the multivariate cox model using QLQ-HCC18 as continuous variables
M5: the multivariate cox model using QLQ-HCC18 as dichotomized variables
M6: the multivariate cox model using HCC18 index score
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validation of the multivariate cox proportional hazard
models. However, bootstrapping has enabled internal
validation of the multivariate models.
HRQOL assessment is important to aid clinical man-
agement in HCC patients. Being an aggressive disease,
patients commonly present at advanced stage when
treatment option is limited, of modest benefit and asso-
ciated with disabling toxicities. HRQOL assessment en-
ables the identification of symptoms/problems, whereby
symptom control and psychosocial support measures
could be offered as part of palliative care in parallel with
anti-neoplastic therapy.
HRQOL tools could further be utilized to provide
prognostic information. HRQOL analyses may poten-
tially supplement available clinical staging systems in
prognostication. External validation of the role of QLQ-
C30 and HCC18 index-scores in prognostication in
HCC patients is warranted. Index-scoring may prove
useful in HRQOL research for other cancer types and
further studies are encouraged.
Conclusions
Both EORTC QLQ-HCC18 and QLQ-C30 measurements
at presentation are prognostic for OS in newly diagnosed
patients with HCC of various stages. Index-scores of QLQ-
HCC18 and QLQ-C30 are highly significant prognostic
factors for OS in newly diagnosed HCC patients. Index-
scoring provides an effective way to summarize, analyze
and interpret raw HRQOL data, and renders QLQ-HCC18
and QLQ-C30 meaningful and communicable in clinical
practice. Index-scores of both EORTC QLQ-C30 and
QLQ-HCC18 could potentially serve as a standardized tool
for future HRQOL research.
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